|NeoStem's revenues rise as stem cell business grows|
|By Phil Cheng, ProActiveInvestors.Com|
|Monday, 04 April 2011 19:53|
Biopharmaceutical company NeoStem (AMEX:NBS) said that its 2010 revenues grew 13% from the prior year.
That was up from 2009 pro forma revenues of $61.7 million.
Since starting out as a provider of adult stem cell collection and storage services, NeoStem has since branched out into cell therapeutics, using stem cells to help cure disease.
In January, the company acquired Progenitor Cell Therapy, which has cell therapy manufacturing facilities, as well as processing and storage facilities for stem cells collected from the umbilical cord at birth, located on the east and west coast of the US.
Through the acquisition, NeoStem also controls 80% of Athelos, a company focused on developing therapeutic cells to treat disorders of the immune system.
Aside from its US services and Chinese generic pharma company, NeoStem also has partnerships with two Chinese hospitals, giving it a foundation on which to build its China stem-cell therapy business.
In 2010, the company spent $16.4 million for the construction of a new pharmaceutical manufacturing facility at Suzhou Erye Pharmaceutical. At year-end, NeoStem had $15.6 million of cash and equivalents.
The company said in its statement that it expects to file its 10-K annual report this week.
Shares closed at $1.74 +0.02 (1.16%) on Monday.
“Proactiveinvestors is a leading news organisation and event business with offices in New York, Sydney, Toronto and London. The Company is a publisher and is not registered with the US Securities Exchange Commission or Ontario Securities Commission. Please read our full terms and conditions here http://www.proactiveinvestors.com/pages/terms”